OPKO Health (NASDAQ:OPK) Issues Quarterly Earnings Results

OPKO Health (NASDAQ:OPK) posted its earnings results on Tuesday. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03), Briefing.com reports. The business had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $182.99 million. OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. OPKO Health’s revenue for the quarter was down 26.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.02) EPS.

OPKO Health Stock Down 3.8 %

NASDAQ OPK opened at $1.25 on Thursday. The business’s 50-day moving average is $1.14 and its 200 day moving average is $1.22. The stock has a market capitalization of $871.24 million, a PE ratio of -5.00 and a beta of 1.81. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.55 and a quick ratio of 1.22. OPKO Health has a 1 year low of $0.85 and a 1 year high of $2.24.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost acquired 1,000,000 shares of OPKO Health stock in a transaction on Wednesday, February 21st. The shares were acquired at an average cost of $0.99 per share, with a total value of $990,000.00. Following the transaction, the chief executive officer now owns 208,368,225 shares in the company, valued at $206,284,542.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders acquired 3,100,000 shares of company stock worth $2,923,000. 47.26% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on OPK shares. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Barrington Research restated an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a research report on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and set a $5.00 price objective on shares of OPKO Health in a research note on Monday, April 1st.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.